almotriptan

Trade name: axert

Small moleculeapproved

Approved

May 7, 2001

Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is marketed under the trade name Axert. Almotriptan is used for treating acute migraine headaches with or without aura (eg, dark spots, flashing lights, wavy lines). Almotriptan binds with high affinity to 5-HT1D, 5-HT1B, and 5-HT1F receptors. Almotriptan has weak affinity for 5-HT1A and 5-HT7 receptors, but has no significant affinity or pharmacological activity at 5-HT2, 5-HT3, 5-HT4, 5-HT6; alpha or beta adrenergic; adenosine (A1, A2); angiotensin (AT1, AT2); dopamine (D1, D2); endothelin (ETA, ETB); or tachykinin (NK1, NK2, NK3) binding sites. — NCATS

Clinical trial activity

9 trials · 7 clinical orgs · 5 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jul 1, 2003 (NCT00210483)

Timeline

2000s

May 7, 2001
Pharmacia & Upjohn — Earliest FDA Approval
May 7, 2001
Pharmacia & Upjohn — NDA Organization
May 7, 2001
Johnson and Johnson — NDA Secondary Org
Jan 1, 2003
Johnson and Johnson — Earliest Phase 3 Sponsor(trial)

2010s

Jul 7, 2015
Teva — Marketing Organization
Nov 9, 2015
Mylan — Marketing Organization
Mar 3, 2016
Ajanta Pharma Ltd — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Serotonin 1b (5-HT1b) receptorAGONIST
HTR1B agonist
Selective
- 5-hydroxytryptamine receptor 1B (HTR1B) ↗
Serotonin 1f (5-HT1f) receptorAGONIST
HTR1F agonist
Selective
- 5-hydroxytryptamine receptor 1F (HTR1F) ↗
Serotonin 1d (5-HT1d) receptorAGONIST
HTR1D agonist
Selective
- 5-hydroxytryptamine receptor 1D (HTR1D) ↗

Approval history

approvedMay 7, 2001

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12

Mol. weight: 335.47 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No
Delivery: Oral
Availability: Prescription Only

Oral

Yes

Parenteral

Topical

Sources

Also known as

1-(((3-(2-(dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine
1-(((3-(2-(dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine
almogran
almogran
almotriptan
almotriptan
almotriptan
almotriptan
almotriptan
almotriptan
almotriptan
almotriptan
almotriptan
almotriptan
almotriptan malate
almotriptan malate
almotriptan malate
almotriptan malate
almotriptan malate
axert
axert
axert
axert
axert
las-31416
las-31416
las-31416
las-31416 d,l-malate acid
las-31416 d,l-malate acid
pnu-180638e
pnu-180638e

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT05214001	Phase 4	Jun 30, 2022	University of Copenhagen
NCT01619176	N/A	Oct 1, 2012	Chinese Academy of Medical Sciences, Jiao Tong University
NCT00432549	Phase 4	Jan 1, 2007	Johnson and Johnson, The New England Center for Headache
NCT00257010	Phase 3	Dec 1, 2005	Janssen Pharmaceutica NV, Johnson and Johnson
NCT00210496	Phase 4	Jun 1, 2005	Janssen Pharmaceutica NV, Johnson and Johnson
NCT00210509	Phase 4	Nov 1, 2004	Janssen Pharmaceutica NV, Johnson and Johnson
NCT00212823	Phase 4	Jun 1, 2004	Johnson and Johnson
NCT00208065	Phase 4	May 1, 2004	Clinvest, Johnson and Johnson
NCT00210483	Phase 3	Jul 1, 2003	Janssen Pharmaceutica NV, Johnson and Johnson

Showing 9 of 9 trials

Page 1 / 1

Organizations

Research & Development (7)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Johnson and Johnson	For profit	7	5	2	2003
Janssen Pharmaceutica NV	For profit	4	0	2	2003
Chinese Academy of Medical Sciences	Academic/Hospital	1	1	1	2012
Clinvest	For profit	1	1	1	2004
Jiao Tong University	Academic/Hospital	1	0	1	2012
The New England Center for Headache	Academic/Hospital	1	1	1	2007
University of Copenhagen	Academic/Hospital	1	1	1	2022

7 organizations

Page 1 / 1

Marketing (6)

Organization	Org type	Relationship	Date
Ajanta Pharma Ltd	For profit	MKTG	Mar 3, 2016
Johnson and Johnson	For profit	NDA2	May 7, 2001
Mylan	For profit	MKTG	Nov 9, 2015
Mylan	For profit	SYN	Nov 9, 2015
Pharmacia & Upjohn	For profit	NDA	May 7, 2001
Teva	For profit	MKTG	Jul 7, 2015